Added to YB: 2025-06-25
Pitch date: 2025-06-23
XVIVO.ST [neutral]
Xvivo Perfusion AB (publ)
-38.86%
current return
Author Info
No bio for this author
Company Info
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden.
Market Cap
SEK 8.8B
Pitch Price
SEK 285.40
Price Target
567.00 (+217%)
Dividend
N/A
EV/EBITDA
64.39
P/E
64.55
EV/Sales
9.96
Sector
Health Care Equipment and Supplies
Category
growth
Initial Report: Xvivo Perfusion AB (XVIVO.ST), 19% 5-yr Potential Upside (Pyae Phyo SHUN, EIP)
XVIVO.ST (premium valuation): Strong position in organ perfusion market w/ lung success (90% share), heart trials promising (44% lower complications). Q4 showed 44% organic growth. Scaling technology addresses organ shortage, but high valuation, regulatory risks, and reliance on organ availability remain concerns. DCF suggests 19% upside to SEK 567/share. US liver/kidney expansion critical.
Read full article (15 min)